On August 30, 2018, UPMC Health Plan announced a value-based contract with Alkermes for VIVITROL®, a long-acting injection of naltrexone for medication-assisted addiction treatment (MAT). The medication is administered once monthly to reduce the risk of relapse in people with opioid use disorder following detoxification. Reimbursement will be linked to positive clinical outcomes among UPMC Health Plan members who use VIVITROL®. William Shrank, M.D., chief medical officer at UPMC Health Plan said the goal is to add value for UPMC members by helping them avoid dependence on opioids and remove barriers to access. Traditional contracts have . . .